Beta-containing bivalent SARS-CoV-2 protein vaccine elicits durable broad neutralization in macaques and protection in hamsters

Autor: Catherine Berry, Vincent Pavot, Natalie G. Anosova, Michael Kishko, Lu Li, Tim Tibbitts, Alice Raillard, Sylviane Gautheron, Sheila Cummings, Dinesh S. Bangari, Swagata Kar, Caroline Atyeo, Yixiang Deng, Galit Alter, Cindy Gutzeit, Marguerite Koutsoukos, Roman M. Chicz, Valerie Lecouturier

Publikováno v: Communications Medicine, Vol 3, Iss 1, Pp 1-16 (2023)

Abstract Background Since the beginning of the COVID-19 pandemic, several variants of concern (VOC) have emerged for which there is evidence of an increase in transmissibility, more severe disease, and/or reduced vaccine effectiveness. Effective COVI

Externí odkaz: https://doaj.org/article/7ddec5d298994b9fb951ab9ada5f2108

Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group studyResearch in context

Autor: Guy de Bruyn, Joyce Wang, Annie Purvis, Martin Sanchez Ruiz, Haritha Adhikarla, Saad Alvi, Matthew I. Bonaparte, Daniel Brune, Agustin Bueso, Richard M. Canter, Maria Angeles Ceregido, Sachin Deshmukh, David Diemert, Adam Finn, Remi Forrat, Bo Fu, Julie Gallais, Paul Griffin, Marie-Helene Grillet, Owen Haney, Jeffrey A. Henderson, Marguerite Koutsoukos, Odile Launay, Federico Martinon Torres, Roger Masotti, Nelson L. Michael, Juliana Park, Doris Maribel Rivera-Medina, Natalya Romanyak, Chris Rook, Lode Schuerman, Lawrence D. Sher, Fernanda Tavares-Da-Silva, Ashley Whittington, Roman M. Chicz, Sanjay Gurunathan, Stephen Savarino, Saranya Sridhar, Allaw Mohammed, Babin Valérie, Babyak Jennifer, Ines Ben-Ghezala, Thomas Breuer, Corinne Breymeier, Anne Conrad, Ciarrah Holmqvist, Cristiana Costa-Araujo, Florence Coux, Christine Dellanno, Bertrand Dussol, Brandon Essink, Jesús Garrido, Pierre-Olivier Girodet, Claudia Gonzalez, Marie-Ange Grosbois, Justin Hammond, Chelsea He, Ciarrah Homlqvist, Kathy Hudzina, Mark Hutchens, Peta-Gay Jackson Booth, Arnel Joaquin, Rama Kandasamy, Jennifer Kasztejna, Michael Keefer, Murray Kimmel, Matthew Kresge, Fabrice Laine, Maeva Lefebvre, Denise Lopez, Malaborbor Perpetua Lourdes, Zoha Maakaroun-Vermesse, Caitlin Malishchak, Lisa Menard, Sandra Mendoza, Patrick Moore, Mounika Mulamalla, Patrick Mulholland, Jean-Francois Nicolas, Onyema Ogbuagu, Juan Ortiz, Ana Paula Perroud, Gina Peyton, Ya-Fen Purvis, Vanessa Raabe, Enrique Rivas, Nadine Rouphael, Beatrice Roy, Lola Sagot, Nessryne Sater, Howard Schwartz, Randall Severance, Jiayuan Shi, Magdalena Sobieszczyk, Charlene Stevens, Tran Phuong Thuy, Ramy Toma, Tina Tong, Sophie Tourneux, John Treanor, Núria Turet, Rachel Froget, Stephen Walsh, Judith White, Victor del Campo Perez, Lina Perez Breva, Pablo Rojo Conejo, Maria Belen Ruiz Antoraz, Toong Chin, Charlotte Fribbens, Adrian Phillipson, Rachel Kaminski, Stevan Emmett, Corey Hebert, Thomas Birch, Russell Roberson, Jeffrey Zacher, Sophie Gelu-Maury, Loron Loryne, Yvonne Davis

Publikováno v: EClinicalMedicine, Vol 62, Iss , Pp 102109- (2023)

Summary: Background: In a parallel-group, international, phase 3 study (ClinicalTrials.gov NCT04762680), we evaluated prototype (D614) and Beta (B.1.351) variant recombinant spike protein booster vaccines with AS03-adjuvant (CoV2 preS dTM-AS03). Meth

Externí odkaz: https://doaj.org/article/1e007f68a3a6477da53dae2f0eb41b2d

Early and Long-Term HIV-1 Immunogenicity Induced in Macaques by the Combined Administration of DNA, NYVAC and Env Protein-Based Vaccine Candidates: The AUP512 Study

Autor: Beatriz Perdiguero, Benedikt Asbach, Carmen E. Gómez, Josef Köstler, Susan W. Barnett, Marguerite Koutsoukos, Deborah E. Weiss, Anthony D. Cristillo, Kathryn E. Foulds, Mario Roederer, David C. Montefiori, Nicole L. Yates, Guido Ferrari, Xiaoying Shen, Sheetal Sawant, Georgia D. Tomaras, Alicia Sato, William J. Fulp, Raphael Gottardo, Song Ding, Jonathan L. Heeney, Giuseppe Pantaleo, Mariano Esteban, Ralf Wagner

Publikováno v: Frontiers in Immunology, Vol 13 (2022)

To control HIV infection there is a need for vaccines to induce broad, potent and long-term B and T cell immune responses. With the objective to accelerate and maintain the induction of substantial levels of HIV-1 Env-specific antibodies and, at the

Externí odkaz: https://doaj.org/article/6036c61a4c684d169531306cb6b2b597

Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations

Autor: Wilton B. Williams, Jinsong Zhang, Chuancang Jiang, Nathan I. Nicely, Daniela Fera, Kan Luo, M. Anthony Moody, Hua-Xin Liao, S. Munir Alam, Thomas B. Kepler, Akshaya Ramesh, Kevin Wiehe, James A. Holland, Todd Bradley, Nathan Vandergrift, Kevin O. Saunders, Robert Parks, Andrew Foulger, Shi-Mao Xia, Mattia Bonsignori, David C. Montefiori, Mark Louder, Amanda Eaton, Sampa Santra, Richard Scearce, Laura Sutherland, Amanda Newman, Hilary Bouton-Verville, Cindy Bowman, Howard Bomze, Feng Gao, Dawn J. Marshall, John F. Whitesides, Xiaoyan Nie, Garnett Kelsoe, Steven G. Reed, Christopher B. Fox, Kim Clary, Marguerite Koutsoukos, David Franco, John R. Mascola, Stephen C. Harrison, Barton F. Haynes, Laurent Verkoczy

Publikováno v: Nature Communications, Vol 8, Iss 1, Pp 1-20 (2017)

An efficient HIV-1 vaccine will likely depend on eliciting broadly neutralizing antibodies (bnAb). Here the authors analyze the B cell repertoire in macaques and knock-in mice in response to sequential immunization with Env variants that induce a bnA

Externí odkaz: https://doaj.org/article/69f91741f8e94cd5827c2664a8377d65

Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study

Autor: Saranya Sridhar, Arnel Joaquin, Matthew I Bonaparte, Agustin Bueso, Anne-Laure Chabanon, Aiying Chen, Roman M Chicz, David Diemert, Brandon J Essink, Bo Fu, Nicole A Grunenberg, Helene Janosczyk, Michael C Keefer, Doris M Rivera M, Ya Meng, Nelson L Michael, Sonal S Munsiff, Onyema Ogbuagu, Vanessa N Raabe, Randall Severance, Enrique Rivas, Natalya Romanyak, Nadine G Rouphael, Lode Schuerman, Lawrence D Sher, Stephen R Walsh, Judith White, Dalia von Barbier, Guy de Bruyn, Richard Canter, Marie-Helene Grillet, Maryam Keshtkar-Jahromi, Marguerite Koutsoukos, Denise Lopez, Roger Masotti, Sandra Mendoza, Catherine Moreau, Maria Angeles Ceregido, Shelly Ramirez, Ansoyta Said, Fernanda Tavares-Da-Silva, Jiayuan Shi, Tina Tong, John Treanor, Carlos A Diazgranados, Stephen Savarino

Publikováno v: The Lancet. Infectious Diseases

Background We evaluated our SARS-CoV-2 prefusion spike recombinant protein vaccine (CoV2 preS dTM) with different adjuvants, unadjuvanted, and in a one-injection and two-injection dosing schedule in a previous phase 1–2 study. Based on interim resu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af3e86897af835c9263827f1202f68fd
https://doi.org/10.1016/s1473-3099(21)00764-7